Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 222 of the 224 references it cites were found in a registry or an index; 43 of the 250 sources its claims cite were checked for support.

Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers

Open access

Abstract

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that purpose, has garnered marked interest over the past two decades as an emerging treatment for major depressive disorder. With increasing evidence of its efficacy in treatment-resistant depression and its potential anti-suicidal action, a great deal of investigation has been conducted on elucidating ketamine’s effects on the brain. Of particular interest and therapeutic potential is the ability of ketamine to exert rapid antidepressant properties as early as several hours after administration. This is in stark contrast to the delayed effects observed with traditional antidepressants, often requiring several weeks of therapy for a clinical response. Furthermore, ketamine appears to have a unique mechanism of action involving glutamate modulation via actions at the N-methyl-D-aspartate (NMDA) and [Formula: see text]-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, as well as downstream activation of brain-derived neurotrophic factor (BDNF) and mechanistic target of rapamycin (mTOR) signaling pathways to potentiate synaptic plasticity. This paper provides a brief overview of ketamine with regard to pharmacology/pharmacokinetics, toxicology, the current state of clinical trials on depression, postulated antidepressant mechanisms and potential biomarkers (biochemical, inflammatory, metabolic, neuroimaging sleep-related and cognitive) for predicting response to and/or monitoring of therapeutic outcome with ketamine.

Overview

CoChat Summary

TL;DR

This review summarizes ketamine’s pharmacology, clinical trial evidence, adverse effects, antidepressant mechanisms, and candidate biomarkers for treatment-resistant depression. It highlights rapid but transient antidepressant and anti-suicidal effects, with a proposed glutamate–AMPA–BDNF–mTORC1 synaptic plasticity mechanism, while noting limited long-term and biomarker data.

Key findings

  • Ketamine produces rapid antidepressant effects within 2–4 h, with 60–70% response rates in treatment-resistant depression (TRD); effects are transient, lasting an average of 1 week after a single infusion and 18–19 days after repeated infusions. Retrospective real-world data showed a 44% response rate after six intravenous ketamine treatments in complex, ultra-resistant patients.
  • Its mechanism is more complex than NMDA receptor antagonism: ketamine preferentially antagonizes NMDA receptors on GABA interneurons, causing disinhibition of glutamatergic neurons, a glutamate surge, AMPA receptor activation, and downstream BDNF/mTORC1 signaling that potentiates synaptic plasticity. Other NMDA antagonists such as memantine, lanicemine, and nitrous oxide do not exert consistent antidepressant effects.
  • Candidate biomarkers include plasma BDNF elevations in responders, reduced response in BDNF Val66Met carriers, plasma D-serine levels predicting response, sleep slow-wave activity increases, pro-cognitive effects at TRD doses, inflammatory/metabolic markers (IL-6, CRP, hsCRP, TNF-α, adiponectin, resistin, BMI, metabolic syndrome), and neuroimaging findings in prefrontal cortex, anterior cingulate cortex, hippocampus, and nucleus accumbens.
  • Intranasal esketamine was FDA-approved in March 2019 for major depression failing two or more antidepressants; a phase III trial of over 200 patients showed significant improvement at 4 weeks, while two other phase III trials failed primary endpoints. Maintenance studies up to 88 weeks reported decreased relapse risk and reassuring safety data to over 1 year.

Methods

  • Narrative review of ketamine as an antidepressant, covering pharmacology/pharmacokinetics, clinical trials, adverse effects, postulated mechanisms, and potential biomarkers.
  • Literature search performed in PubMed/MEDLINE and Web of Science Core Collection for English-language papers from 2000 to 2019, using specified topics such as ketamine as an antidepressant, mechanisms of action, biomarkers, enantiomers/metabolites, inflammation, metabolism, sleep, adverse effects, cognition, and neuroimaging.
  • Synthesis is qualitative; no systematic review, meta-analysis, or formal quality appraisal is described.

Limitations

  • Stated in the paper: no long-term RCTs exist; many studies have small sample sizes; findings are contradictory for some mechanisms and biomarkers (e.g., 2R,6R-HNK, mTOR/rapamycin, opioid system); large head-to-head clinical comparisons of esketamine, R-ketamine, and racemic ketamine have not been reported; sleep data are limited to short-term intravenous infusions; neuroimaging data are limited by small samples and few investigations.
  • Evident from the text: as a narrative review, it does not systematically assess study quality or pool results quantitatively, and much mechanistic evidence comes from animal models, so biomarker and mechanism conclusions remain preliminary.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/2045125320916657

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Chemical structure of ketamine, with the chiral center indicated by an asterisk.
Figure 1. Chemical structure of ketamine, with the chiral center indicated by an asterisk.CC BY-NC · PubMed Central

Verification

Claims the paper makes

22 Valid · 3 Not valid · 124 Not checked · 31 Own results and interpretations

96 more claims · 6 with their cited sources checked

Create a free account to see all 180 claims and to verify the 206 references still open.

See all claims — free account
  • It may state two separate claims as one. 61
  • Probably not a substantial claim. 26
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 224 references

Research works printed but not linked: 16

  1. Baker G, 2009, Wiley encyclopedia of chemical biology
  2. 10.1177/2045125316631267 · DOI · Paper page
  3. Tan Y, 2019, Pharmacol Biochem Behav, 188
  4. Albott CS, 2018, J Clin Psychiatry, 79
  5. Rosenblat JD, 2019, J Clin Psychiatry, 80
  6. Meisner R, 2019, Harvard Health Blog
  7. Wlodarczyk A, 2019, Psychiatr Danub, 31, 530
  8. Szarmach J, 2019, Psychiatr Danub, 31, 585
  9. Dong C, 2017, Int J Neuropsychopharmacol, 20, 228
  10. Moda-Sava RN, 2019, Science, 364
  11. Abdallah CG, bioRxiv, 2018
  12. Singh NS, 2016, PLoS One, 11
  13. Wu C, 2019, Neurobiol Learn Mem, 167
  14. Godin O, 2019, J Clin Psychiatry, 80
  15. Rong C, 2018, Int J Environ Res Public Health, 15
  16. Abdallah CG, 2018, Chronic Stress (Thousand Oaks, Calif), 2

Cited by

See all 214

Metadata

Authors
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M.
Affiliations
University of Alberta (CA)
Corresponding author
Baker, Glen B.
Venue
Therapeutic Advances in Psychopharmacology
Published
2020-01
Volume
10
Pages
2045125320916657-2045125320916657
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W3025130047
Cited by
209
References
224
Citations by year
2026: 24 · 2025: 27 · 2024: 59 · 2023: 33 · 2022: 41 · 2021: 22 · 2020: 3
FWCI
14.83
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
university of alberta (TRPGB-UAB)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ketamine, major depressive disorder, treatment-resistant depression, rapid antidepressant effects, NMDA receptor, AMPA receptors, glutamate modulation, brain-derived neurotrophic factor, mTOR signaling, synaptic plasticity, predictive biomarkers, antidepressant response prediction, suicide prevention, neuroimaging biomarkers, cognitive biomarkers, inflammatory markers, metabolic biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. https://app.cochat.ai/papers/10.1177/2045125320916657
The paper
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020). Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320916657

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.